Connect with Us
602 Park Point Drive, Suite 225, Golden, CO 80401 – +1 303.495.2073
© 2025 Medical Affairs Professional Society (MAPS). All Rights Reserved Worldwide.
The Medical Affairs Professional Society (MAPS) is pleased to share our 2024 Digital, Advanced Analytics and Artificial Intelligence (AI) in Medical Affairs report. This report is based on findings from 32 leading organizations representing the Pharmaceutical, Biotech, and Medical and Diagnostic Device sectors, and reflects broad leadership thinking about the current and future states of Medical Affairs (MA) AI capability and challenges.
Survey design and analysis: Boston Consulting Group led the preparation, execution and analyses of the GenAI survey and moderated the Ambassador GenAI and Advanced Analytics workshop during the MAPS conference on March 24th, 2024.
Survey respondents: 34 representatives from 32 companies responded to our survey.
Participating companies: Thank you to participants from 3M, Abbott, AbbVie, Amgen, Astellas, AstraZeneca, Baxter, Bayer, bioMérieux, BioNTech, BMS, Eisai, Lilly, Gilead, Ipsen, Jazz Pharmaceuticals, Kyowa Kirin, Lundbeck, Mallinckrodt, Merck & Co, Mundipharma, Novartis, Otsuka, Regeneron, Sanofi, Sumitomo Pharma, Takeda, Teva, UCB, Varian, Vertex, and Viatris for your valuable feedback and insights.
The opinions expressed here are those of members of the MAPS Ambassador Alliance and do not necessarily represent the perspectives of their respective companies.
Experts from Lumanity discuss cross-functional alignment of Integrated Evidence Generation Planning (IEGP) from perspectives of strategy, clinical/regulatory, commercial and patient engagement.
This series of the Elevate Podcast illuminates the Inspiration and Impact, content Compliance & Approval, MSL utilization, Training & Evolution, the Technology Stack, and the Future of Modular Content.
From the Spreadsheet Age to the Age of Generative AI: Where is your organization on the continuum of Insights Management? (And why no one “age” fits the needs of all teams.)
As the sources of data and technologies needed to make sense of data expand, opportunities exist for further integrating RWE and HEOR alongside traditional approaches when planning data generation activities to support new product registration, access, and use.
Getting the most impact from a publication requires being able to define who the audience is and how to reach them, across both journals and online channels, especially in complex/niche cases. In this podcast, we discuss the benefits of taking an analytical approach.
Medical Affairs is in the unique position to drive health equity through three main roles: catalyser, capabilities enhancer, and cross-functional collaborator, emphasizing the need for deliberate strategies and actions to close health gaps and improve outcomes for underserved populations.
Getting the most impact from a publication requires being able to define who the audience is and how to reach them, across both journals and online channels, especially in complex/niche cases. In this podcast, we discuss the benefits of taking an analytical approach.
Tim Mikelhashvili, CEO of Amedea Pharma, discusses innovation in Medical Affairs leadership. And previews his 2024 Medical Affairs Innovation Olympics!
Publishing a scientific study can feel like squeezing an eyedropper into the ocean and it is the job of the Publications team to ensure this publication has impact — especially when it has the potential to change clinical practice. Here we learn practical tips straight from the source – namely, experts at Wiley.
602 Park Point Drive, Suite 225, Golden, CO 80401 – +1 303.495.2073
© 2025 Medical Affairs Professional Society (MAPS). All Rights Reserved Worldwide.